Clinical perspectives - Biologics in IBD: What's all the fuss?

Canadian Journal of Gastroenterology

Volumn 15, Issue 12, 2001, Pages 799-804

  Steinhart, Hillary ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Biologics; Inflammatory bowel disease

Indexed keywords

5 ACETYLSALICYLIC ACID; ALICAFORSEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; INTEGRIN ANTIBODY; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PARACETAMOL; PREDNISOLONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL MUCOSA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; THROMBOCYTOPENIA; ULCERATIVE COLITIS;

EID: 0035718217     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/605398     Document Type: Article

References (37)

1. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
2. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
3. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies
4. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
5. Involvement of interleukin-4 and -10 in inflammatory bowel disease
6. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR)
7. Interleukin-10-deficient mice develop chronic enterocolitis
8. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease
9. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
10. A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease
11. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis
12. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
13. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
14. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
15. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
16. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
17. Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571
18. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC)
19. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice
20. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis
21. Expression and polarization of intercellular adhesion molecule-1 on human intestinal epithelia: Consequences for CD11b/CD18-mediated interactions with neutrophils
22. In situ expression of E-selectin and intercellular adhesion molecule-1 in chronic inflammatory diseases of the gastrointestinal tract
23. 2 integrin/ICAM expression in Crohn's disease
24. In-situ endothelial cell adhesion molecule expression in ulcerative colitis. E-selectin in-situ expression correlates with clinical, endoscopic and histological activity and outcome
25. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis
26. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats
27. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular (ICAM-1)
28. Antibodies to intercellular adhesion molecule-1 ameliorate the inflammatory response in acetic acid-induced inflammatory bowel disease
29. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a guthoming integrin alpha 4 beta 7
30. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells
31. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody
32. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
33. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
34. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
35. 7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease
36. Annual cost of care for Crohn's disease